Psychedelics Beyond the CNS
A Thesis Validated: The Somatic Frontier
For the past decade, the resurgence of psychedelic science has been overwhelmingly defined by psychiatry. Research and capital have concentrated on central nervous system (CNS) conditions, leaving the somatic and peripheral potential of these powerful molecular structures largely unexplored.
Â
However, a critical shift is underway. The recent landmark study published in Science (DOI: 10.1126/science.aec6116) provides profound validation for a thesis we have long championed at Prodelic Technologies LLC: The next major evolution in neuroplastogen therapeutics will be non-hallucinogenic, somatic, and fundamentally reliant on targeted delivery.
Â
By demonstrating that 5-HT2A receptor agonists can prevent the onset of Chemotherapy-Induced Peripheral Neuropathy (CIPN), the scientific community has opened a massive new frontier. Prodelic anticipated this shift, quietly building the underlying formulation architecture required for a market that is now stepping into the light.
Preventing Chemotherapy-Induced Peripheral Neuropathy with TBG
Redefining Neuropathy: From Inevitable to Preventable
Â
Chemotherapy-induced peripheral neuropathy is a devastating toxicity that causes persistent pain, numbness, and functional loss in cancer survivors. Historically treated as an unavoidable collateral damage of oncology regimens, CIPN often necessitates chemotherapy dose reductions that can compromise overall survival rates.
Â
The Science publication completely reframes this clinical challenge. Researchers discovered that chemotherapy impairs the movement of mitochondria within nerve axons. 5-HT2A activation rescues this function, preserving the energy distribution required to keep sensory nerves alive.
Crucially, the study proved that non-hallucinogenic 5-HT2A agonists (such as Tabernanthalog / TBG) fully reproduce this neuroprotection. Hallucinogenic activity is entirely unnecessary to shield peripheral nerves from structural damage.
The Mechanism of Peripheral Rescue:
The Delivery Imperative
Â
While the neuroprotective mechanism of 5-HT2A agonists is a scientific breakthrough, unlocking its real-world clinical value introduces a significant engineering hurdle. Systemic administration of these compounds—whether oral or intravenous—exposes the patient to unnecessary gastrointestinal irritation, potential cardiovascular risks, and hepatic first-pass metabolism.
Â
For oncology patients already enduring intensive systemic toxicities, adding a new systemic burden is clinically prohibitive. The goal is precise: protect the vulnerable peripheral nerves in the extremities without flooding the patient's entire circulation.
Â
This is where the translation of promising neuroscience relies entirely on advanced drug delivery. Prodelic Technologies has engineered a comprehensive formulation portfolio specifically designed to bypass systemic bottlenecks and localize therapeutic payloads exactly where they are needed:
Â
⚬   Lipid Nanoparticles (LNPs): Engineered to encapsulate and protect sensitive neuroplastogens, our LNP formulations facilitate highly targeted cellular uptake at the peripheral site, maximizing bioavailability at the sensory nerve endings while minimizing systemic leakage.
​
⚬   Localized Hydrogel Matrices: Designed for precise dermal and epidermal release, these tunable matrices provide sustained, controlled dosing directly over vulnerable peripheral nerves. They can be formulated for transdermal patches or topical applications that bypass the GI tract entirely.
​
⚬   Advanced Emulsion Systems: By utilizing optimized micro- and nano-emulsions, we can create tailored release profiles. This allows the delivery of the neuroprotectant to be perfectly synced with the specific duration of peak chemotherapy toxicity, acting as a localized chemical shield precisely when the nerves are under attack.
Building the Infrastructure for Somatic Neurology
The discovery that non-hallucinogenic psychedelics can heal the physical body marks a turning point in modern medicine. Yet, a molecule is only as effective as its delivery system.
At Prodelic Technologies, our vision has always extended beyond the CNS. By integrating benchtop precision with scalable formulation science, we have developed the delivery architecture that makes somatic neuroprotection possible. We are proud to provide the technological foundation that will help transform treatments for CIPN—and other peripheral neuropathies—from an abstract concept into an accessible, non-invasive clinical reality.